Shares of Absci Co. (NASDAQ:ABSI – Get Free Report) have received a consensus rating of “Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.40.
Several analysts recently commented on the stock. Guggenheim assumed coverage on shares of Absci in a research report on Wednesday. They issued a “buy” rating and a $10.00 price target for the company. Morgan Stanley assumed coverage on shares of Absci in a research report on Wednesday, July 3rd. They issued an “overweight” rating and a $7.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Absci in a research report on Thursday, August 15th. Finally, KeyCorp cut their price objective on shares of Absci from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th.
Check Out Our Latest Report on Absci
Absci Trading Down 5.2 %
Absci (NASDAQ:ABSI – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The firm had revenue of $1.27 million for the quarter, compared to analyst estimates of $2.05 million. Absci had a negative return on equity of 44.24% and a negative net margin of 2,838.89%. During the same quarter last year, the firm earned ($0.27) EPS. As a group, research analysts expect that Absci will post -0.8 EPS for the current fiscal year.
Hedge Funds Weigh In On Absci
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC boosted its stake in shares of Absci by 153.8% during the 4th quarter. Hsbc Holdings PLC now owns 407,579 shares of the company’s stock worth $1,769,000 after acquiring an additional 247,019 shares in the last quarter. Salem Investment Counselors Inc. purchased a new stake in shares of Absci during the 1st quarter worth approximately $122,000. Cannon Global Investment Management LLC purchased a new stake in shares of Absci during the 1st quarter worth approximately $104,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Absci during the 1st quarter worth approximately $2,390,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Absci during the 1st quarter worth approximately $1,477,000. Institutional investors and hedge funds own 52.05% of the company’s stock.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Featured Stories
- Five stocks we like better than Absci
- Compound Interest and Why It Matters When Investing
- 2 Uranium Stocks Fueling Growth From the Nuclear Power Surge
- How to Invest in the Best Canadian StocksĀ
- Analysts See 180% Upside for Rent the Runway: Should You Buy?
- Stock Sentiment Analysis: How it Works
- Ready for Growth? Barrick Gold Stock Could Be the Answer
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.